KLRC1 and acute myeloid leukemia: Additionally, it was found that the inhibitory receptor NKG2A is a dominant checkpoint for the ML NK-cell phenotype, and that CD8α+ donor NK cells correlate to treatment failure against AML acute myeloid leukemia (AML) (60).